低温氧合灌注(HOPE)预防肝细胞癌肝移植术后癌症复发:HOPE4Cancer国际多中心随机对照试验研究方案
HOPE4Cancer是一项国际多中心平行组随机对照试验,比较冷储存后低温氧合灌注(HOPE)与常规冷储存对肝细胞癌肝移植受者移植术后无复发生存的影响,计划1:1分配,主要终点为移植术后HCC无复发生存期。
要点
- HOPE4Cancer为国际多中心随机对照试验,比较HOPE与常规冷储存。
- 纳入已确诊HCC的成人受者,接受脑死亡捐献(DBD)肝移植。
- 主要终点为移植术后HCC无复发生存期,即移植后存活且无HCC复发的时间间隔。
核心结论
- HOPE4Cancer研究冷储存联合缺血期间应用的HOPE在DBD肝移植中是否在移植术后HCC无复发生存方面优于常规冷储存。
- 结果将首次提示移植前离体HOPE与移植未灌注肝脏相比是否具有抗癌潜力。
研究设计与样本
- 国际多中心、平行组、随机对照试验,HOPE组与常规冷储存组按1:1分配。
- 纳入已确诊HCC的成人受者,接受DBD肝移植。
- 干预为初始冷储存后行HOPE,对照为单纯常规冷储存。
- 最低灌注时长定义为2小时,灌注一般持续至受者肝切除完成。
- 常规冷储存于4°C按当地标准治疗使用预冷保存液进行。
主要发现
- 主要终点为移植术后HCC无复发生存期,即患者移植后存活且无HCC复发的时间间隔。
- 次要终点包括主要结局所考虑事件的单一组分(HCC复发、HCC相关死亡、非HCC的其他原因死亡)、循环肿瘤DNA、血液中高迁移率族蛋白B1、排斥活动指数及患者经历的肝脏相关并发症数量。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A frequent and increasing indication for liver transplantation (LT) is hepatocellular carcinoma (HCC). However, despite strict selection criteria, HCC recurrence after LT occurs in a relevant proportion of patients and is associated with an unfavorable prognosis. Hypothermic oxygenated perfusion (HOPE) is a novel machine liver perfusion approach to optimize liver grafts before implantation and has been suggested to decrease graft inflammation with potential anti-cancer effects. METHODS: HOPE4Cancer is an international, multicentric, parallel group, randomized controlled trial comparing HOPE performed after initial cold storage (intervention) with conventional cold storage alone (control) in a 1:1 allocation ratio. Adult recipients with proven HCC will be included for transplantation of a DBD (donation after brain death) Liver graft. The minimum perfusion duration is defined at 2 h and perfusion is generally continued until the recipient hepatectomy is completed. The conventional cold storage at 4 °C will be performed with a precooled preservation solution according to the local standard of care. The primary endpoint is defined as post-transplant HCC recurrence-free survival, i.e., the time interval a patient is alive without HCC recurrence after transplantation. Secondary endpoints are the single components of the events considered for the primary outcome (i.e., HCC recurrence, HCC-related death, death from any other causes than HCC), circulating tumor DNA, high-mobility-group-protein B1 in the blood, the Rejection Activity index, and the number of liver-related complications experienced by the patient. DISCUSSION: HOPE4Cancer investigates if cold storage plus end-ischemically applied HOPE in DBD LT is superior to conventional cold storage of liver grafts in terms of post-transplant HCC recurrence-free survival. The results will indicate for the first time whether ex situ HOPE before transplant has an anti-cancer potential compared to transplantation of un-perfused livers. TRIAL REGISTRATION: ClinicalTrials.gov NCT06717919. Registered on December 5, 2024.
引用
- Eden J, Müller PC, Kuemmerli C, et al. Hypothermic oxygenated perfusion (HOPE) against cancer recurrence after liver transplantation for hepatocellular carcinoma-study protocol for an international multicenter randomized controlled trial (HOPE4Cancer). Trials. 2025. PMID: 41013675. doi:10.1186/s13063-025-09120-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。